Ms. Kari R. Gran
President and Co-founder
Kari Gran Inc.
1735 Westlake Ave N, #110
Seattle , WA 98109
United StatesFEI 3015320016Issued Nov 30, 2022Division of Pharmaceutical Quality Operations IV
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3015320016.
Violations5
Issue DateNov 30, 2022
Product TypeDrugs
StatusOpen
Letter Details
Firm
Kari Gran Inc.
Location
Ms. Kari R. Gran
President and Co-founder
Kari Gran Inc.
1735 Westlake Ave N, #110
Seattle , WA 98109
United States
FEI Number
3015320016
Country
United States
Issue Date
November 30, 2022
Issuing Office
Division of Pharmaceutical Quality Operations IV
Product Type
Drugs
Status
Open
Summary
Kari Gran Inc., a drug manufacturer, was cited for significant Current Good Manufacturing Practice (CGMP) violations in the production of over-the-counter SPF sunscreen products. The company failed to perform adequate release testing for multiple batches prior to distribution, including insufficient testing of zinc oxide as the active ingredient, and released batches to the market before receiving test results. Additionally, the firm did not establish appropriate stability testing programs or written protocols to determine proper storage conditions and expiration dates, and did not conduct routine finished product testing on subsequent batches after initial production.
Kari Gran Inc. FDA Warning Letter, November 30, 2022